Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 5.5% – Should You Sell?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) dropped 5.5% during trading on Tuesday . The company traded as low as $21.61 and last traded at $21.77. Approximately 36,787 shares were traded during trading, a decline of 87% from the average daily volume of 280,797 shares. The stock had previously closed at $23.04.

Analyst Upgrades and Downgrades

DNTH has been the subject of a number of recent research reports. TD Cowen initiated coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They set a “buy” rating for the company. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Oppenheimer raised their target price on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research report on Monday, November 11th. Finally, Raymond James raised shares of Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. Eight analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $46.43.

Dianthus Therapeutics Price Performance

The stock has a market capitalization of $568.62 million, a price-to-earnings ratio of -7.68 and a beta of 1.74. The business’s 50-day simple moving average is $24.02 and its two-hundred day simple moving average is $26.51.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). The business had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.07 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. As a group, sell-side analysts expect that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Institutional Trading of Dianthus Therapeutics

Hedge funds have recently made changes to their positions in the company. Jane Street Group LLC purchased a new stake in shares of Dianthus Therapeutics during the third quarter valued at approximately $556,000. Barclays PLC raised its stake in shares of Dianthus Therapeutics by 390.5% during the third quarter. Barclays PLC now owns 41,684 shares of the company’s stock valued at $1,141,000 after purchasing an additional 33,185 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Dianthus Therapeutics by 860.5% during the second quarter. Bank of New York Mellon Corp now owns 80,935 shares of the company’s stock valued at $2,095,000 after purchasing an additional 72,509 shares during the period. HighVista Strategies LLC purchased a new stake in shares of Dianthus Therapeutics during the third quarter valued at approximately $542,000. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Dianthus Therapeutics by 142.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company’s stock valued at $4,543,000 after purchasing an additional 97,362 shares during the period. Hedge funds and other institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.